3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
3
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
3
Other hematologic neoplasm
2
Head & Neck
2
Gastrointestinal
2
Plasma cell
1
Myeloid
1
Lymphoid
1
Gynecologic
1
Genitourinary
1
Dermatologic
1
CNS
1
Conditions
Vomiting
1
Melanoma
1
Carcinoma, Renal Cell
1
Interventions
Nivolumab
114
Ipilimumab
114
pembrolizumab
108
aldesleukin
76
Cyclophosphamide
70
fludarabine phosphate
51
Interleukin-2
48
Temozolomide
41
Dacarbazine
36
trametinib
33
dabrafenib
30
Bevacizumab
30
sargramostim
29
Radiotherapy
29
incomplete Freund's adjuvant
27
fludarabine
27
Vemurafenib
25
Radiosurgery
25
Carboplatin
25
Paclitaxel
23
binimetinib
22
Biopsy
22
CTLA-4 Antigen
21
Peripheral Blood Stem Cell Transplantation
20
encorafenib
19
cemiplimab
19
atezolizumab
19
Mycophenolic Acid
19
HhAntag691
19
Aminolevulinic Acid
18
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Aprepitant
×
Dermatologic
×
Clear all
NCT01874119
2018-06-07
HDIL2/Emend
St. Louis University
Phase 2
Terminated
13 enrolled
7 charts